Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.
about
First-line first? Trends in thiazide prescribing for hypertensive seniorsChemical Composition and Vasorelaxant and Antispasmodic Effects of Essential Oil from Rosa indica L. PetalsClinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of HypertensionEffect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data[Treatment patterns of hypertension in 1996. Data from the Quebec Family Practice, University of Sherbrooke registry]A novel method of guideline development for the diagnosis and management of mild to moderate hypertension.Contemporary practice patterns in the management of newly diagnosed hypertension.Compliance in hypertension: why don't patients take their pills?Direct and indirect randomized trials of screening: the A's and D's of evidence-based clinical practice guidelinesDo beta-blockers have a role in treating hypertension? NoEfficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.[Hypertension. A new way to approach an old problem]Treating hypertension. Are the right drugs given to the right patients?Homeopathy. Friend or foe?Canadian Hypertension Education Program: the evolution of hypertension management guidelines in Canada."Drug may have caused huge number of deaths": lessons learned during an encounter with The Fifth Estate.
P2860
Q24792251-C4B5E7E2-7282-4FA9-A5A5-D508508AD363Q28608166-E42A982B-02DA-4B64-B415-D004830FE33CQ30499043-50777339-C8E5-4264-A0FF-7ED5F5E78595Q30499045-14D7711A-8206-4DC4-88D2-0AB09941D7B3Q31915694-CC552809-E7B0-4BBD-9211-C4F46E9A1043Q32085627-34CD7EAA-55A9-4702-899D-236244B50561Q33644592-E2C71A44-4F10-44B8-B0F5-0542C16A8E83Q34024487-59A9DA59-1C0B-4438-A3EF-D89C2B9AD0CAQ34030377-2CB1E4D8-1567-4B77-A3F8-DD80505DD0E0Q34037381-646E74B8-945D-43E1-AD1B-4921130720D3Q35951354-9E431E33-DBAD-43C3-9291-4CC9CFFB2B8AQ35981791-1FE8755F-6466-4B08-865F-F71F37DA3019Q36284959-8106F3F3-55E7-44A9-BC43-856E073C3571Q36514849-AA1E3A38-D610-4694-A54D-CCDA4A9554A4Q36653189-2A18D422-CF90-4457-944B-AF77747D318BQ37098406-3E4F1316-6D71-411A-9A4E-FFF51702DC80Q41506351-65134DDA-87A7-4D80-B6EC-8EDB6B24DD96
P2860
Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Report of the Canadian Hyperte ...... ent of essential hypertension.
@ast
Report of the Canadian Hyperte ...... ent of essential hypertension.
@en
Report of the Canadian Hyperte ...... ent of essential hypertension.
@nl
type
label
Report of the Canadian Hyperte ...... ent of essential hypertension.
@ast
Report of the Canadian Hyperte ...... ent of essential hypertension.
@en
Report of the Canadian Hyperte ...... ent of essential hypertension.
@nl
prefLabel
Report of the Canadian Hyperte ...... ent of essential hypertension.
@ast
Report of the Canadian Hyperte ...... ent of essential hypertension.
@en
Report of the Canadian Hyperte ...... ent of essential hypertension.
@nl
P2093
P2860
P1476
Report of the Canadian Hyperte ...... ent of essential hypertension.
@en
P2093
P2860
P304
P407
P577
1993-09-01T00:00:00Z